Monday, November 04, 2019 1:54:48 PM
DCVax
- does not require expensive DNA modification like Car-T
- does not require expensive R&D Doctors or Phds to research cancer antigens on different solid tumors
- does not require expensive computer equipments to do gene sequencing and manipulation
- since the above are not needed, expensive R&D buildings are not needed
- does not cause adverse side effects.
- increases quality of life
- still in its infancy, advantage to be the first player
Guess if you are the head of the R&D, how much money can you save if you forgo hiring too many Phds in research, Scientists in gene sequencing and Bio-techniciean in cancer antigens?
How much money can be saved by forgoing building sophisticated hightech computing powers researching characteristics of cancers?
How much money can be saved by forgoing hiring lawyers to protect your company from being sued due to adverse side effect?
How much money can be saved by forgoing hiring marketing and sales professional since the DCVax increases quality of life and extend people lives which speak by itself and thus not really necessary hiring too many marketing folks?
All of those potentially can be replaced by Dendritic Cells which have been activated properly to recognize cancer antigens by injecting them to the tumors peripheral which can then work wonders.
My opinion.
Recent NWBO News
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/01/2024 10:04:38 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/02/2023 01:31:35 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/16/2023 10:11:54 PM
- Epazz, Inc. (OTC Pink: EPAZ) ZenaDrone Demonstration to Defense Departments of UAE and Saudi Arabia • InvestorsHub NewsWire • 11/15/2023 12:19:31 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/09/2023 09:30:39 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration ZenaDrone 1000 • InvestorsHub NewsWire • 11/09/2023 01:00:34 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration ZenaDrone 1000 Extreme Weather Demo • InvestorsHub NewsWire • 11/07/2023 12:29:43 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/09/2023 08:36:14 PM
FEATURED Cannabix Technologies Launches New Compact Breath Logix Workplace Series and Prepares for Delivery to South Africa • May 7, 2024 8:51 AM
Moon Equity Holdings, Corp. Announces Acquisition of Wikolo, Inc. • MONI • May 7, 2024 9:48 AM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM